Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Publications from the Centre for Immuno-Oncology

MHC class I and II-deficient humanized mice are suitable tools to test the long-term antitumor efficacy of immune checkpoint inhibitors and T-cell engagers.

Eguren-Santamaria I. et al, (2024), Journal for immunotherapy of cancer, 12

CD137 (4-1BB) and T-Lymphocyte Exhaustion.

Molero-Glez P. et al, (2024), Clin Cancer Res, OF1 - OF3

Testing new anticancer drugs before curative locoregional therapies: MDICT 2024 recommendations

(2024), ESMO Open, 9, 103649 - 103649

Double-stranded RNA to mimic viral infection for cancer immunotherapy.

Martinez-Riaño A. et al, (2024), Clinical cancer research : an official journal of the American Association for Cancer Research

Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040.

Melero I. et al, (2024), Annals of oncology : official journal of the European Society for Medical Oncology, 35, 537 - 548

CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials.

Segal NH. et al, (2024), Nature communications, 15

Spatially resolved tissue imaging to analyze the tumor immune microenvironment: beyond cell-type densities.

Lopez Janeiro A. et al, (2024), Journal for immunotherapy of cancer, 12

Data from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

Peters S. et al, (2024)

Data from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

Peters S. et al, (2024)

Supplementary Figure S1 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

Peters S. et al, (2024)

Supplementary Figure S1 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

Peters S. et al, (2024)

Supplementary Figure S2 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

Peters S. et al, (2024)

Supplementary Figure S2 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

Peters S. et al, (2024)

Supplementary Figure S3 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

Peters S. et al, (2024)

Supplementary Figure S3 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

Peters S. et al, (2024)

Supplementary Figure S4 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

Peters S. et al, (2024)

Supplementary Figure S4 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

Peters S. et al, (2024)

Supplementary Figure S5 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

Peters S. et al, (2024)

Supplementary Figure S5 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

Peters S. et al, (2024)

Supplementary Methods S1 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

Peters S. et al, (2024)

Load More

1
2
3
4
5
6
7
...
»